Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

UCB : Transparency notification of Vanguard Health Care Fund

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/11/2012 | 08:41pm CET

Participation on March 30, 2012 (according to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings).

Brussels (Belgium), April 11, 2012 - 7.30 p.m. (CET) - regulated information - Vanguard Health Care Fund (having its registered offices c/o The Vanguard Group, 455 Devon Park Drive, Wayne, PA 19087 - USA) acquired 5,821,811 UCB shares with voting rights (on a total number of 183,365,052) on March 30, 2012, representing 3.17% of UCB's share capital, which means that Vanguard Health Care Fund crossed the threshold of notification of 3%.

UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608


For further information

Antje Witte, Investor Relations, UCB

T +32.2.559.9414, [email protected]

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

UCB Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
01/12 Pfizer's Barrett named CEO of Novartis Oncology
01/11 AMGEN : European Medicines Agency Accepts Filing for EVENITY
01/09 UCB : European Medicines Agency Accepts Filing for EVENITYTM
01/04 DATA ON PSORIATIC ARTHRITIS DISCUSSE : ...
2017 European stocks sink on Flynn guilty plea after choppy session
2017 European stocks sink on Flynn guilty plea after choppy session
2017 UCB : Research Conducted at UCB S.A. Has Provided New Information about Clinical..
2017 UCB : New study data shows prior osteoporotic fractures put women at increased r..
2017 DERMIRA : and UCB Agree to End Collaboration Agreement for CIMZIA
2017 UCB : Dermira and UCB Agree to End Collaboration Agreement for CIMZIA …
More news
News from SeekingAlpha
01/08 EMA accepts UCB's marketing application for osteoporosis med romosozumab
2017 Dermira to returns rights to psoriasis candidate Cimzia back to UCB; shares d..
2017 UCB's (UCBJF) CEO Jean Tellier on Q2 2017 Results - Earnings Call Transcript
2017 FDA rejects Amgen's marketing application for osteoporosis candidate romosozu..
2017 Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but..
Financials (€)
Sales 2017 4 387 M
EBIT 2017 1 019 M
Net income 2017 669 M
Debt 2017 617 M
Yield 2017 1,73%
P/E ratio 2017 18,91
P/E ratio 2018 16,68
EV / Sales 2017 3,20x
EV / Sales 2018 2,96x
Capitalization 13 440 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 66,5 €
Spread / Average Target -3,7%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB4.41%16 266
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287